CBD offers hope for life-threatening brain injury complication
Cannabidiol as an adjunct in refractory paroxysmal sympathetic hyperactivity following severe traumatic brain injury: a case report.
AI Summary
Paroxysmal Sympathetic Hyperactivity (PSH) is a serious complication affecting 5-33% of severe traumatic brain injury (TBI) patients, causing dangerous episodes of rapid heart rate, extreme blood pressure spikes, and uncontrolled body movements. A 44-year-old patient with severe TBI developed severe PSH with 4-6 episodes daily despite treatment with seven different medications at maximum doses—making this a case of refractory PSH that had exhausted conventional treatment options.
When cannabidiol (CBD) was added as an adjunctive therapy at approximately 3 mg/kg/day, the results were striking: within the first week, episode frequency dropped from 4-6 daily to less than one per 48 hours, and severity scores dropped by 43%. By the second week, PSH episodes resolved completely, allowing doctors to discontinue powerful sedative and opioid infusions. Importantly, CBD was well-tolerated with no adverse effects, including no liver damage or excessive sedation.
While this is a single case report and cannot prove CBD causes the improvement, the dramatic response after conventional therapies failed suggests CBD's known neuroprotective and autonomic-modulating properties may offer new hope for TBI patients with refractory PSH. The findings warrant larger clinical trials to explore CBD's potential role in treating this life-threatening complication.
📄
Original Abstract
Related Research
Similar Studies
More Neuroprotection research papers you might find interesting.
Review links lifestyle and the ECS in MS, but finds no proven…
Small ALS trial found no significant disease-progression difference
Preclinical review finds CBD effects on nitric oxide vary by enzyme
Explore More Research
Stay informed about the latest cannabis science.